Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | ADK | P55263 | 5/20 | 0.31 |
| ▸ | AHCY | P23526 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323202 | 0.90 | PRMT5 (0.34) | PRMT5WDR77ADKAHCY | |
| SCHEMBL20488512 | 0.88 | ADK (0.43) | ADKAHCY | |
| SCHEMBL17549903 | 0.87 | HTR2B (0.31) | ADK | |
| SCHEMBL23273904 | 0.80 | ADK (0.30) | ADKAHCY | |
| SCHEMBL23273847 | 0.80 | ADK (0.30) | ADKAHCY | |
| SCHEMBL9285043 | 0.79 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL28636985 | 0.79 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL30003589 | 0.79 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL19667186 | 0.79 | PRMT5 (0.35) | PRMT5WDR77ADK | |
| SCHEMBL19344078 | 0.78 | PRMT5 (0.38) | PRMT5WDR77ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 59/4885ADK 1639/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 52/4885ADK 2078/4885 |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 59/4885ADK 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.